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Reply to Dr. Goodwin 
To the Editor: 
Dr. Goodwin misinterprets our emphasis on the importance of the mitogen dose 
dependency of the indomethacin (IND) effect on lymphocyte functions in 
evaluating such experimental data. Our major concern stems from the fact that the 
optimal concentration of mitogen is a variable entity and depends upon culture 
conditions as well as the individual donor source (l-3). Contrary to the statement 
that all their studies on prostaglandin (PG) regulation of immune functions used 
suboptimal mitogen concentrations, Dr. Goodwin and his colleagues have 
previously claimed that “all further experiments were performed at optimal 
concentrations of the mitogen” (4). A similar statement was made in one of their 
other publications (5). Their experimental evidence implicating a role for 
endogenous PGs on the immune response in human physiology (5) and pathology 
(4) was based on studies employing a single mitogen concentration. In our paper (3) 
we discussed how the use of a single mitogen concentration could give rise to a 
misleading interpretation. 
We would like to point out that our skepticism on the effect of endogenous PGs on 
the immune response was based on several observations. In particular, we 
observed that exogenously added PGs suppress mitogenic responses at all mitogen 
concentrations tested including the optimal mitogenic dose, whereas IND enhances 
the transformation response only at suboptimal mitogen doses and fails to cause 
enhancement at the optimal concentration of the mitogen. If IND were acting 
through the inhibition of PG synthesis one would expect an enhancement of the 
transformation response even at an optimal concentration of the mitogen, i.e., the 
reciprocal of the PG effect. These observations lead us to suggest that the effect of 
IND on the mitogenic response is mediated through some other pharmacological 
activity, such as its effect on cyclic AMP-dependent protein kinase (6). 
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